The stock trades near the $16.50 take-private price, limiting upside. The operational weakness in the core critical illness segment (15.3% EBITDA decline) is concerning but likely overshadowed by the pending merger. Monitor for stockholder vote and regulatory approvals, any delay or termination risk would expose downside to fair value in the $12-14 range based on deteriorating fundamentals.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 1 $16.38entry
- T+1 · 7mo ago 0.00%α +0.34% · $16.38
- T+5 · 6mo ago −0.18%α −2.53% · $16.35
- T+20 · 6mo ago +0.81%α −4.45% · $16.51
- T+60 · due 4mo ago Pending
Price Chart
How similar events traded
Executive Summary
Select Medical reported Q1 2026 revenue of $1.42B (+5.0% YoY) but EPS of $0.35 declined 20.5% YoY, missing the $0.43 consensus. Operating income fell 12.7% and Adjusted EBITDA dropped 6.5% as the critical illness recovery hospital segment saw a 15.3% EBITDA decline. The company maintained its 2026 guidance and declared a $0.0625 dividend. Separately, the pending take-private merger at $16.50/share (no financing condition, HSR waiting period expired) continues to progress toward a mid-2026 close, which will likely cap the stock near the deal price.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $1.421B (+5.0% YoY) vs $1.353B prior year
- GAAP EPS $0.35 vs $0.44 YoY (-20.5%), missed consensus of $0.43
- Operating income fell 12.7% to $98.4M from $112.7M
- Adjusted EBITDA declined 6.5% to $141.6M from $151.4M
- Critical illness recovery hospital EBITDA dropped 15.3% to $73.4M; margin compressed from 13.6% to 11.5%
- Outpatient rehab EBITDA fell 9.4% to $22.0M; margin down from 7.9% to 6.8%
- Rehab hospital segment was the bright spot: EBITDA +15.1% to $81.1M, margin 23.0%
- 2026 guidance maintained: revenue $5.6B-$5.8B, Adj. EBITDA $520M-$540M, EPS $1.22-$1.32
- Pending take-private merger at $16.50/share; HSR waiting period expired April 27, 2026; expected close mid-2026
- Equity award vesting deferred for Chairman Ortenzio and EVP Jackson by one year
- Quarterly dividend of $0.0625/share declared
Financial Impact
EPS miss of ~18.6% vs consensus ($0.35 actual vs $0.43 est); operating income decline of $14.3M YoY; Adj. EBITDA decline of $9.9M YoY
Risk Factors
- Merger fails to close, stock would reprice to reflect declining earnings trajectory
- Critical illness recovery hospital margins continue compressing (11.5% vs 13.6% last year)
- Outpatient rehab segment margin erosion (6.8% vs 7.9%) may persist
- Labor cost inflation pressuring cost of services (+6.3% vs revenue +5.0%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-053056 |
| Document: tm2613082d1_8k.htm | 0001104659-26-053056 |
| Document: 0001104659-26-053056-index-headers.html | 0001104659-26-053056 |
| Document: 0001104659-26-053056-index.html | 0001104659-26-053056 |
| Document: 0001104659-26-053056.txt | 0001104659-26-053056 |
| 8-K Data (Synthetic) | 0001104659-26-053056 |
Track record
8 reports on SEM
The track record builds as more bullish or bearish reports settle.
Filters
- Jul 13, 202618w ago 15-12G Neutral 4/10 No price data
- Jul 1, 202619w ago 25-NSE Neutral 9/10 Entry $16.52 No price data
- Jul 1, 202619w ago 8-K Bullish 8/10 Entry $16.52 No price data
- Jun 26, 202620w ago 8-K Bullish 7/10 Entry $16.53 No price data
- Apr 30, 202628w ago 8-K Bearish 6/10 Viewing Entry $16.38 to $16.51 ▼ −0.81% +4.45% vs SPY
- Apr 15, 202630w ago PREM14A Bullish 8/10 Entry $16.38 to $16.45 ▲ +0.43% −5.62% vs SPY
- Mar 4, 202636w ago DEFA14A Neutral 3/10 Entry $16.25 to $16.29 ▲ +0.25% +4.66% vs SPY
- Mar 3, 202636w ago DEFA14A Bullish 9/10 Entry $16.26 to $16.29 ▲ +0.18% +4.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers